Drug · CHEMBL429

LABETALOL

7 sourcespipelines-2026-09-18-0.3.1

Cite this record

ConductScience Library. LABETALOL. Drugs and targets, record CHEMBL429. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL429

On this page

Drug

Names and IDs as ChEMBL gives them, through Open Targets.

Name: LABETALOL; ChEMBL
ChEMBL ID: CHEMBL429; ChEMBL
Type: Small molecule; ChEMBL
Other names: AH-5158A FREE BASE, Ibidomide, Normozide, SCH-15719W FREE BASE; ChEMBL
Other form: LABETALOL HYDROCHLORIDE, CHEMBL1200323; Drugs and targets
DrugBank: DB00598; DrugBank
InChIKey: SGUAFYQXFOLMHL-UHFFFAOYSA-N; ChEMBL
Open Targets' highest stage: Approval, for 2 of its 13 diseases, from ATC and TTD; Open Targets

Targets9

The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.

Target	Protein	Mechanism	Action	Gene in Genes
ADRA1A	Adrenergic receptor	Adrenergic receptor antagonist	ANTAGONIST	https://conductscience.org/library/genes/148
ADRA1B	Adrenergic receptor	Adrenergic receptor antagonist	ANTAGONIST	https://conductscience.org/library/genes/147
ADRA1D	Adrenergic receptor	Adrenergic receptor antagonist	ANTAGONIST	https://conductscience.org/library/genes/146
ADRA2A	Adrenergic receptor	Adrenergic receptor antagonist	ANTAGONIST	https://conductscience.org/library/genes/150
ADRA2B	Adrenergic receptor	Adrenergic receptor antagonist	ANTAGONIST	https://conductscience.org/library/genes/151
ADRA2C	Adrenergic receptor	Adrenergic receptor antagonist	ANTAGONIST	https://conductscience.org/library/genes/152
ADRB1	Adrenergic receptor	Adrenergic receptor antagonist	ANTAGONIST	https://conductscience.org/library/genes/153
ADRB2	Adrenergic receptor	Adrenergic receptor antagonist	ANTAGONIST	https://conductscience.org/library/genes/154
ADRB3	Adrenergic receptor	Adrenergic receptor antagonist	ANTAGONIST	https://conductscience.org/library/genes/155

Source ChEMBL

Diseases13

The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Disease	Open Targets' stage	Stage reported by	Reports	Of them trials	Its drugs
hypertensive disorder	Approval	TTD	15	14	https://conductscience.org/library/drugs?q=MONDO_0005044
preeclampsia	Phase 3	ClinicalTrials.gov	9	9	https://conductscience.org/library/drugs?q=MONDO_0005081
intracerebral hemorrhage	Phase 2/3	ClinicalTrials.gov	3	3	https://conductscience.org/library/drugs?q=MONDO_0013792
Pain	Phase 2	ClinicalTrials.gov	2	2	https://conductscience.org/library/drugs?q=HP_0012531
Tachycardia	Phase 2	ClinicalTrials.gov	2	2	https://conductscience.org/library/drugs?q=HP_0001649
ischemic stroke	Phase 2/3	ClinicalTrials.gov	2	2	https://conductscience.org/library/drugs?q=MONDO_1060198
Increased blood pressure	Phase 2	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=HP_0032263
Nasolacrimal duct obstruction	Unknown	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=HP_0000579
cocaine dependence	Phase 2	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=MONDO_0005186
hemorrhagic stroke	Unknown	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=EFO_0020921

1 to 10 of 13Source Open Targets

See all 13 diseases

Trials62

Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.

Trial	Title	Phase	Participants	Results first posted	Named as	Linked by	Source
NCT02299414	Chronic Hypertension and Pregnancy (CHAP) Project	Phase 4	2,408	2023-05-17	labetalol	Its name	ClinicalTrials.gov
NCT00765648	Evaluation of Intravenous Cardene(Nicardipine)and Labetalol Use in the Emergency Department	Phase 4	226	2014-12-11	labetalol	Its name	ClinicalTrials.gov
NCT04116112	Blood Pressure After Endovascular Stroke Therapy-II	Phase 2	120	2023-10-12	labetalol	Its name	ClinicalTrials.gov
NCT03506724	Response to Anti-hypertensives in Pregnant and Postpartum Patients	Phase 4	109	2021-05-24	labetalol	Its name	ClinicalTrials.gov
NCT01114971	Labetalol and Esmolol: Vital Signs and Post Operative Pain Management	Phase 4	75	2020-02-20	labetalol	Its name	ClinicalTrials.gov
NCT04615624	Furosemide vs. Placebo for Severe Antepartum Hypertension	Phase 3	65	2024-04-18	labetalol	Its name	ClinicalTrials.gov
NCT02168309	Oral Nifedipine Versus Oral Labetalol		50	2017-12-13	labetalol	Its name	ClinicalTrials.gov
NCT03661346	Esmolol vs. Labetalol in Endoscopic Sinus Surgery	Phase 2	28	2021-02-08	labetalol	Its name	ClinicalTrials.gov
NCT04343235	Postpartum Management of Gestational Hypertensive Disorders Using Furosemide	Phase 4	13	2023-10-23	labetalol	Its name	ClinicalTrials.gov
NCT01912677	Oral Antihypertensive Regimens for Management of Hypertension in Pregnancy	Phase 4	894		labetalol	Its name	ClinicalTrials.gov

1 to 10 of 62

See all 62 trials

Comparisons in its trials44

Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Anti-hypertensive Therapy to Goal <140/90 mmHg vs No Anti-hypertensive Unless BP is Severe (≥160/105 mmHg: Superimposed Preeclampsia	295 of 1,208	373 of 1,200	2,408	NCT02299414	Trial comparisons
Anti-hypertensive Therapy to Goal <140/90 mmHg vs No Anti-hypertensive Unless BP is Severe (≥160/105 mmHg: Neonatal Hospital Stay of 3 or More Days	590 of 1,208	592 of 1,200	2,408	NCT02299414	Trial comparisons
Anti-hypertensive Therapy to Goal <140/90 mmHg vs No Anti-hypertensive Unless BP is Severe (≥160/105 mmHg: Hypoglycemia	191 of 1,208	195 of 1,200	2,408	NCT02299414	Trial comparisons
Anti-hypertensive Therapy to Goal <140/90 mmHg vs No Anti-hypertensive Unless BP is Severe (≥160/105 mmHg: Low Birth Weight	232 of 1,208	277 of 1,200	2,408	NCT02299414	Trial comparisons
Anti-hypertensive Therapy to Goal <140/90 mmHg vs No Anti-hypertensive Unless BP is Severe (≥160/105 mmHg: Bronchopulmonary Dysplasia (BPD)	8 of 1,208	14 of 1,200	2,408	NCT02299414	Trial comparisons
Anti-hypertensive Therapy to Goal <140/90 mmHg vs No Anti-hypertensive Unless BP is Severe (≥160/105 mmHg: 5-min Apgar Score	68 of 1,208	80 of 1,200	2,408	NCT02299414	Trial comparisons
Anti-hypertensive Therapy to Goal <140/90 mmHg vs No Anti-hypertensive Unless BP is Severe (≥160/105 mmHg: Superimposed Gestational Hypertension	132 of 1,208	156 of 1,200	2,408	NCT02299414	Trial comparisons
Anti-hypertensive Therapy to Goal <140/90 mmHg vs No Anti-hypertensive Unless BP is Severe (≥160/105 mmHg: Bradycardia	31 of 1,208	35 of 1,200	2,408	NCT02299414	Trial comparisons
Anti-hypertensive Therapy to Goal <140/90 mmHg vs No Anti-hypertensive Unless BP is Severe (≥160/105 mmHg: Necrotizing Enterocolitis (NEC)	2 of 1,208	2 of 1,200	2,408	NCT02299414	Trial comparisons
Anti-hypertensive Therapy to Goal <140/90 mmHg vs No Anti-hypertensive Unless BP is Severe (≥160/105 mmHg: Cesarean Delivery	592 of 1,208	582 of 1,200	2,408	NCT02299414	Trial comparisons

1 to 10 of 44

See all 44 comparisons in its trials

Papers from its trials44

The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
40672455	RESULT	1	PubMed
36352567	RESULT	1	PubMed
35323883	RESULT	1	PubMed
25611642	RESULT	1	PubMed
23055089	RESULT	1	PubMed
42495732	DERIVED	1	PubMed
42457247	DERIVED	1	PubMed
42212393	DERIVED	1	PubMed
42067698	DERIVED	1	PubMed
41744094	DERIVED	1	PubMed

1 to 10 of 44

See all 44 papers from its trials

Tests in its trials0

The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.

None in this release.

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
ClinicalTrials.gov: 2026-11-05; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
Papers the trials list, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
Tests named in the trials, as ScienceGraph matched them: 2026-11-12; ConductCognition

Sources 7

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ConductCognition's list of its testsOur own data
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this drug from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/drugs/v1/CHEMBL429

GET https://conductscience.org/api/drugs/v1/CHEMBL429/trials?page=2

API reference For AI assistants